{"id":528534,"date":"2021-02-02T16:46:01","date_gmt":"2021-02-02T16:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=528534"},"modified":"2021-02-02T16:46:01","modified_gmt":"2021-02-02T16:46:01","slug":"crohns-disease-market-report-insights","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-market-report-insights_528534.html","title":{"rendered":"Crohn&#8217;s Disease Market Report Insights"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Crohn&#039;s Disease Market Report Insights \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Crohn&#039;s Disease Market Report Insights \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Crohn&#8217;s Disease (CD) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Crohn&#8217;s Disease (CD), historical and forecasted epidemiology as well as the Crohn&#8217;s Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>What is Crohn&#8217;s Disease?&nbsp; <\/strong><\/p>\n<p style=\"text-align: justify;\">Crohn&rsquo;s Disease is a type of inflammatory bowel disease (IBD). It is an inflammatory condition of the gastrointestinal tract, which most commonly affects the end of the small bowel (the ileum), the beginning of the colon, and any part of the gastrointestinal (GI) tract from the mouth to the anus.<\/p>\n<p style=\"text-align: justify;\"><strong>How many people are affected by<\/strong> <strong>Crohn&#8217;s Disease<\/strong><strong>?<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In UK, it is estimated that at least 115,000 people have Crohn&#8217;s Disease.<\/li>\n<li>Crohn&#8217;s Disease can occur at any age and is more prevalent among adolescents and young adults between the ages of 15 and 35.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">The standardized approved evidence-based therapies for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\"><strong>Crohn&#8217;s Disease treatment<\/strong><\/a> include infliximab (Remicade; Janssen Biotech), adalimumab (Humira; AbbVie), certolizumab Pegol (Cimzia; UCB), natalizumab (Tysabri; Biogen), vedolizumab (Entyvio; Millennium Pharmaceuticals), and Ustekinumab (Stelara; Janssen Biotech). These therapies have been approved for moderate to severe Crohn&#8217;s Disease.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample pages @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-market\"><strong>Crohn&#8217;s Disease Market trends<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>How will Crohn&#8217;s Disease Market change in upcoming years?&nbsp; <\/strong><\/p>\n<p style=\"text-align: justify;\">The growth of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\"><strong>Crohn&#8217;s Disease market<\/strong><\/a> include increased understanding of the disease, introduction of novel therapies in the Crohn&#8217;s Disease market, and other innovative treatment options to overcome the limitation of the current <strong>Crohn&#8217;s Disease treatment regimen<\/strong> and improved patient-of-care.<\/p>\n<p style=\"text-align: justify;\">Expected launch of emerging therapies such as AbbVie&rsquo;s risankizumab, Genentech&rsquo;s etrolizumab, and other therapies shall increase the <strong>market size of Crohn&rsquo;s Disease<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Crohn&#8217;s Disease <\/strong><strong>Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c5413f54d00a4cbfa27f2b84d278007b.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The launch of emerging therapies such as Filgotinib (Gilead Sciences), Risankizumab (Abbvie), Etrolizumab (Genetech), PDA-001 (Celularity) and other compelling treatments are expected to increase the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/crohns-disease-cd-market\"><strong>Crohn&rsquo;s Disease market size<\/strong><\/a> in upcoming years.<\/p>\n<p style=\"text-align: justify;\">Key players such as Gilead Sciences, Celgene Corporation, Abbvie, Genetech, and many others are involved in developing therapies for Crohn&rsquo;s Disease.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample pages @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/crohns-disease-cd-market\"><strong>Crohn&#8217;s Disease Market trends<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=crohns-disease-market-report-insights\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=crohns-disease-market-report-insights\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Crohn&#8217;s Disease (CD) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Crohn&#8217;s Disease (CD), historical and forecasted epidemiology as well as the Crohn&#8217;s Disease (CD) market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/crohns-disease-market-report-insights_528534.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-528534","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/528534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=528534"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/528534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=528534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=528534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=528534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}